Kolexia
Jamme Philippe Oncologie médicale
Jamme Philippe
Oncologie médicale
Hôpital Huriez
Lille, France
60 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Mélanome Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinomes Carcinome pulmonaire à petites cellules Tumeurs cutanées Carcinome épidermoïde Métastase tumorale Carcinome épidermoïde de la tête et du cou

Collaborateurs

Voir plus
Mortier Laurent
Mortier Laurent
Hôpital Huriez, Lille, France
Cortot Alexis
Cortot Alexis
Hôpital Albert Calmette, Lille, France
Descarpentries Clotilde
Descarpentries Clotilde
Centre de Biologie - Pathologie, Lille, France
Copin Marie-Christine
Copin Marie-Christine
Centre de formation des professionnels de santé, Angers, France

Industries

Voir plus
A+A
18 collaboration(s)
Dernière en 2023
Novartis
13 collaboration(s)
Dernière en 2022
Pierre Fabre
10 collaboration(s)
Dernière en 2023
MSD
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Melanoma research   07 février 2024
362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Abstract Book of the ESMO Asia Congress 2023, 1-3 December 2023   01 novembre 2023
516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Abstract Book of the ESMO Asia Congress 2023, 1-3 December 2023   01 novembre 2023
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Molecular oncology   14 juillet 2023
MelBase: Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Essai Clinique (Assistance publique – Hôpitaux de Paris)   07 juillet 2023
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.
Targeted oncology   13 juin 2023
A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors: Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Essai Clinique (Merus N.V.)   07 mai 2023
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.
Cancer immunology, immunotherapy : CII   17 avril 2023
Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
Melanoma research   03 mars 2023
Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
The oncologist   24 janvier 2023